• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Factor V Leiden and PT G20210A mutations in cancer patients with and without venous thrombosis.

作者信息

Eroglu A, Kurtman C, Ulu A, Cam R, Akar N

出版信息

J Thromb Haemost. 2005 Jun;3(6):1323-4. doi: 10.1111/j.1538-7836.2005.01346.x.

DOI:10.1111/j.1538-7836.2005.01346.x
PMID:15946230
Abstract
摘要

相似文献

1
Factor V Leiden and PT G20210A mutations in cancer patients with and without venous thrombosis.伴有和不伴有静脉血栓形成的癌症患者中的凝血因子V莱顿突变和凝血酶原G20210A突变
J Thromb Haemost. 2005 Jun;3(6):1323-4. doi: 10.1111/j.1538-7836.2005.01346.x.
2
Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.凝血酶原G20210A变异体和因子V莱顿突变携带者发生静脉血栓形成的风险及其与口服避孕药的相互作用。
Haematologica. 2000 Dec;85(12):1271-6.
3
Factor V Leiden and prothrombin G20210A variant are risk factors for venous thromboembolism in the Argentinean population.
Thromb Haemost. 2000 Mar;83(3):509-10.
4
The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.凝血因子V Leiden和凝血酶原G20210A突变的杂合携带者发生复发性深静脉血栓形成的风险。
N Engl J Med. 1999 Sep 9;341(11):801-6. doi: 10.1056/NEJM199909093411104.
5
Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A.因子 V 莱顿和凝血酶原 G20210A 纯合子携带者和双重杂合子携带者复发性静脉血栓形成的风险。
Circulation. 2010 Apr 20;121(15):1706-12. doi: 10.1161/CIRCULATIONAHA.109.906347. Epub 2010 Apr 5.
6
[Factor V Leiden and PTG20210A gene mutation in patients with venous thrombosis and healthy blood donors].[静脉血栓形成患者及健康献血者中的凝血因子V莱顿突变和凝血酶原G20210A基因突变]
Zhonghua Yi Xue Za Zhi. 1999 Dec;79(12):900-2.
7
Prevalence of the G1691A mutation in the factor V gene (factor V Leiden) and the G20210A prothrombin gene mutation in the Thai population.泰国人群中凝血因子V基因G1691A突变（凝血因子V莱顿突变）和凝血酶原基因G20210A突变的患病率。
Am J Hematol. 2000 Oct;65(2):119-22. doi: 10.1002/1096-8652(200010)65:2<119::aid-ajh5>3.0.co;2-8.
8
Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients.
J Thromb Thrombolysis. 2007 Feb;23(1):31-4. doi: 10.1007/s11239-006-9001-z.
9
Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behçet's disease and deep vein thrombosis.意大利白塞病合并深静脉血栓形成患者的凝血因子V莱顿突变和凝血酶原基因G20210A突变
Arthritis Rheum. 2004 Apr 15;51(2):177-83. doi: 10.1002/art.20237.
10
[Factor V Leiden and prothrombin G20210A among Chilean patients with venous and arterial thrombosis].[智利静脉和动脉血栓形成患者中的凝血因子V莱顿突变和凝血酶原G20210A突变]
Rev Med Chil. 2005 Dec;133(12):1425-33. doi: 10.4067/s0034-98872005001200003. Epub 2006 Jan 27.

引用本文的文献

1
Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants.癌症相关静脉血栓栓塞症：新型抗凝药物时代的治疗与预防更新。
Front Cardiovasc Med. 2016 Jul 28;3:24. doi: 10.3389/fcvm.2016.00024. eCollection 2016.
2
Assessing risk of venous thromboembolism in the patient with cancer.评估癌症患者静脉血栓栓塞的风险。
J Clin Oncol. 2009 Oct 10;27(29):4839-47. doi: 10.1200/JCO.2009.22.3271. Epub 2009 Aug 31.
3
Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients.
J Thromb Thrombolysis. 2007 Feb;23(1):31-4. doi: 10.1007/s11239-006-9001-z.
4
Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients with and without thrombosis.伴有和不伴有血栓形成的癌症患者中纤溶酶原激活物抑制剂-1基因4G/5G多态性
J Thromb Thrombolysis. 2006 Oct;22(2):111-2. doi: 10.1007/s11239-006-9054-z.